After decades-long struggles with microRNA-based therapeutics, Regulus hits paydirt in the clinic and in the marketplace. Is it the beginning of a trend or a one-off?
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. microRNAs blaze into the clinic. Nat Biotechnol 43, 1583–1585 (2025). https://doi.org/10.1038/s41587-025-02870-y
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02870-y
